All sponsors

Regeneron Pharmaceuticals $REGN

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS91
PHASE 3 / 2-338
RECRUITING52
READOUTS ≤12 MONTHS16
READOUT SLIPPED >6 MO47%

Delay Index: of 58 active trials registered more than a year ago, 27 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.6 months). See all sponsors →

Open Regeneron Pharmaceuticals on the live radar map → 📅 $REGN readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
cemiplimab
NCT03916627
P2Active, not recruitingNon-small Cell Lung Cancer; Hepatocellular Carcinoma652025-03-31 (+35 mo)
NIMBLE
NCT05070858
P3Active, not recruitingGeneralized Myasthenia Gravis2882025-07-08 (+16 mo)
OPTIMA
NCT05394116
P3Active, not recruitingFibrodysplasia Ossificans Progressiva632025-07-17 (+4 mo)
ELARA
NCT06491914
P3Active, not recruitingNeovascular Age-Related Macular Degeneration; Diabetic Macular Edema11262025-08-26 (-5 mo)
ENGAGE
NCT05831176
P2Active, not recruitingEosinophilic Gastritis (EoG); Eosinophilic Duodenitis (EoD)222026-02-23 (-17 mo)
Fianlimab
NCT05352672
P3Active, not recruitingMelanoma15462026-03-12 (+17 mo)
ELM-2
NCT03888105
P2Active, not recruitingB-cell Non-Hodgkin Lymphoma (B-NHL)5152026-06-17 (+29 mo)
Fianlimab
NCT06161441
P2Active, not recruitingResectable Non-small Cell Lung Cancer1952026-08-24 (+11 mo)
cemiplimab
NCT06190951
P2Active, not recruitingMelanoma1512026-11-02 (-50 mo)
COMBINE-EGFR-1
NCT04626635
P1/2Active, not recruitingAdvanced Solid Tumors5482026-11-13 (+21 mo)
Olatorepatide
NCT07431086
P2Active, not recruitingOverweight or Obesity1202026-11-13
FERVENT-1
NCT06421636
P2Active, not recruitingNon-Transfusion Dependent Beta-Thalassemia (NTDT)192026-12-03 (-14 mo)
ASCEND-QW
NCT07477704
P2Active, not recruitingHypercholesterolemia4382026-12-29
Fianlimab
NCT05608291
P3Active, not recruitingMelanoma15642027-01-15 (-33 mo)
ROXI-ATLAS
NCT07175428
P2RecruitingAtrial Fibrillation (AF)12002027-02-09 (-2 mo)
ROXI-APEX
NCT07015905
P3RecruitingVenous Thromboembolism (VTE)20002027-02-20
fianlimab
NCT06246916
P3RecruitingMelanoma5602027-03-22 (+2 mo)
Ubamatamab
NCT03564340
P1/2RecruitingRecurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer8902027-05-10 (+61 mo)
ROXI-ASPEN
NCT07213778
P3RecruitingSymptomatic Venous Thromboembolism (VTE)20002027-05-17 (-2 mo)
Mibavademab
NCT07220772
P3RecruitingMonogenic Obesity42027-06-18 (+2 mo)
REGN5093
NCT04077099
P1/2Active, not recruitingNSCLC952027-07-06 (+42 mo)
ALN-PNP
NCT05648214
P1/2RecruitingHealthy Volunteers; Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)1722027-08-10 (+44 mo)
ALN-CIDEB
NCT06836609
P1/2Active, not recruitingMetabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis1182027-08-17 (+6 mo)
fianlimab
NCT05785767
P2/3Active, not recruitingAdvanced Non-Small Cell Lung Cancer1492027-09-28 (-14 mo)
REGN5678
NCT03972657
P1/2RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC)3452027-11-15 (+40 mo)
Vonsetamig
NCT05092347
P1/2Active, not recruitingChronic Kidney Disease (CKD)432027-11-22 (+32 mo)
Cemiplimab
NCT03969004
P3Active, not recruitingCutaneous Squamous Cell Carcinoma4152028-01-07 (+31 mo)
Olatorepatide
NCT07685808
P2RecruitingOverweight or Obesity3602028-01-21
BNT116
NCT05557591
P2Active, not recruitingAdvanced Non-Small Cell Lung Cancer512028-01-26 (+9 mo)
KYRIAD
NCT07235917
P2RecruitingFunctional Hypothalamic Amenorrhea; FHA342028-01-28
ILLUMINATE
NCT07318597
P2RecruitingPulmonary Arterial Hypertension (PAH)992028-02-27
OLYMPIA-1
NCT06091254
P3RecruitingFollicular Lymphoma (FL)8222028-02-29 (-12 mo)
OLYMPIA-3
NCT06091865
P3RecruitingDiffuse Large B-cell Lymphoma (DLBCL)9042028-03-30 (-4 mo)
NASHGEN-2
NCT05519475
P2Active, not recruitingMetabolic Dysfunction-Associated SteatoHepatitis (MASH)1202028-04-27 (+20 mo)
LAGO
NCT07220785
P3RecruitingGeneralized Lipodystrophy282028-05-19
OLYMPIA-4
NCT06230224
P3Active, not recruitingB-Cell Non-Hodgkin Lymphoma (B-NHL)2162028-05-29 (+11 mo)
FDC fianlimab+cemiplimab
NCT06769698
P2RecruitingHead and Neck Squamous Cell Carcinoma (HNSCC)1202028-06-04 (+13 mo)
EoE-TOTs
NCT07112378
P3RecruitingEosinophilic Esophagitis (EoE)202028-06-19 (-2 mo)
Ubamatamab
NCT06787612
P2RecruitingOvarian Cancer; Fallopian Tube Cancer3972028-06-30 (+2 mo)
SIENNA
NCT06541704
P3RecruitingAge-related Macular Degeneration (AMD); Geographic Atrophy (GA)9752028-07-31 (+13 mo)
LINKER-AL2
NCT06292780
P1/2RecruitingRelapsed/Refractory Systemic Light Chain Amyloidosis2202028-08-20
ACCESS-EXT
NCT05744921
P3RecruitingParoxysmal Nocturnal Hemoglobinuria2022028-10-10 (+6 mo)
ANCHOR-POC
NCT07271186
P2RecruitingDiabetic Kidney Disease (DKD)1952028-10-13
REGN5668
NCT04590326
P1/2RecruitingOvarian Cancer; Fallopian Tube Cancer6122028-11-08 (+32 mo)
Olatorepatide
NCT07830329
P2RecruitingHidradenitis Suppurativa3002028-11-24
RISE-1
NCT07896265
P3Not yet recruitingOverweight or Obesity Without Diabetes30002028-12-19
ALN-CIDEB
NCT07631637
P2RecruitingMetabolic Dysfunction-Associated Steatohepatitis; MASH3602029-01-29
CHORD
NCT05788536
P1/2RecruitingCongenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)362029-02-26 (-13 mo)
ALN-CIDEB
NCT07854782
P3RecruitingMetabolic Dysfunction-Associated Steatotic Liver Disease; MASLD15002029-03-03
ROXI-INCLINE
NCT07430956
P3RecruitingAtrial Fibrillation (AF)26282029-03-28
ALN-CIDEB
NCT07933328
P2Not yet recruitingAlcohol-Associated Liver Disease; ALD1202029-05-07
LINKER-MM5
NCT07222761
P3RecruitingRelapsed and/or Refractory Multiple Myeloma (RRMM)9152029-05-21
REGN-2Cat
NCT07675811
P3RecruitingAllergic Conjunctivitis5702029-05-31
ROXI-PEAK
NCT07697599
P3RecruitingVenous Thromboembolism (VTE)19082029-06-25
OLYMPIA-2
NCT06097364
P3Active, not recruitingFollicular Lymphoma (FL)7332029-07-29 (-5 mo)
ROXI-PALISADE
NCT07318610
P3RecruitingPeripheral Artery Disease (PAD)70502029-08-18
ROXI-EVEREST
NCT07626411
P3RecruitingAtrial Fibrillation (AF)153642029-09-11
BAHAMA
NCT07675824
P1/2RecruitingPrimary Open Angle Glaucoma (POAG); Ocular Hypertension (OHT)2712029-09-14
REGN9220
NCT07887750
P1/2Not yet recruitingDiffuse Large B-Cell Lymphoma (DLBCL)362029-11-01
ALN-CFB
NCT07187401
P1/2RecruitingParoxysmal Nocturnal Hemoglobinuria (PNH); Persistent Anemia242029-11-29 (+2 mo)
Cemiplimab
NCT06465329
P2Active, not recruitingNon Small Cell Lung Cancer; NSCLC1842029-12-04 (+29 mo)
ROXI-DAISEN
NCT07876492
P3Not yet recruitingSecondary Stroke61062029-12-15
fianlimab
NCT05800015
P2/3Active, not recruitingNon-small Cell Lung Cancer1602030-01-16 (-16 mo)
Pozelimab
NCT07154745
P3RecruitingParoxysmal Nocturnal Hemoglobinuria352030-01-18 (-12 mo)
ROXI-CAT-I
NCT07410117
P3RecruitingCancer-Associated Thrombosis (CAT)11202030-01-23
BrILliance
NCT06413680
P1/2RecruitingMelanoma; Clear-Cell Renal-Cell Carcinoma (ccRCC)2402030-02-03 (-2 mo)
ALN-PNP
NCT07527910
P2RecruitingMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)2042030-03-15
REGN4336
NCT05125016
P1/2RecruitingMetastatic Castration-resistant Prostate Cancer2282030-03-28 (+44 mo)
Cemiplimab
NCT06585410
P3RecruitingCutaneous Squamous Cell Carcinoma (CSCC)3692030-05-03 (+11 mo)
Ubamatamab
NCT07154290
P2RecruitingNon Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer3002030-06-10
OPTIMA-2
NCT07559513
P3Not yet recruitingFibrodysplasia Ossificans Progressiva; FOP182030-07-08
Fianlimab+cemiplimab
NCT06848088
P2Active, not recruitingMelanoma282030-10-09 (+12 mo)
REGN15505
NCT07594106
P1/2RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC)2652030-10-27
Cemiplimab
NCT07808515
P2Not yet recruitingLocally Advanced Basal Cell Carcinoma1352030-11-13
ALN-6457
NCT07832370
P1/2Not yet recruitingPrion Disease602031-02-27
REGN13089-M404-M2980
NCT07863024
P1/2Not yet recruitingAdvanced Solid Tumors3202031-03-10
OLYMPIA-5
NCT06149286
P3RecruitingRelapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)5802031-04-30 (+23 mo)
ROXI-CAT-II
NCT07493304
P3RecruitingVenous Thromboembolism (VTE)16002031-07-18
REGN21353
NCT07850921
P1/2Not yet recruitingMetastatic Castration-Resistant Prostate Cancer; mCRPC1922031-07-28
GOALS
NCT06351592
P1/2RecruitingAmyotrophic Lateral Sclerosis (ALS); Mutation in the Superoxide Dismutase-1 (SOD1) Gene542032-03-21 (+35 mo)
LINKER-MGUS1
NCT06140524
P2RecruitingMonoclonal Gammopathy of Undetermined Significance (MGUS); Smoldering Multiple Myeloma (SMM)1162032-05-18 (+3 mo)
Cemiplimab
NCT07567469
P1/2Not yet recruitingHigh-Grade Glioma (HGG); Posterior Fossa-A Ependymoma1202032-08-27
Linvoseltamab
NCT05955508
P2Active, not recruitingSmoldering Multiple Myeloma (SMM)402033-01-25 (+9 mo)
LINKER-MM1
NCT03761108
P1/2RecruitingMultiple Myeloma3872033-03-30
LINKER-MM3
NCT05730036
P3RecruitingRelapsed Refractory Multiple Myeloma (RRMM)4102033-04-19 (+6 mo)
LINKER-SMM2
NCT07393282
P3RecruitingHigh Risk Smoldering Multiple Myeloma (HR-SMM)2702033-07-27
Linvoseltamab
NCT07455851
P1/2RecruitingRelapsed Refractory Multiple Myeloma (RRMM)1502033-09-30
COSTIMM
NCT06669247
P1/2RecruitingRelapsed/Refractory Multiple Myeloma1862033-11-11 (+1 mo)
BEYOND-9
NCT06379789
P1/2RecruitingHemophilia B1302034-08-14 (+25 mo)
LINKER-AL1
NCT07901725
P3Not yet recruitingNewly Diagnosed Amyloidosis; Amyloidosis Stage I-IIIA3822035-07-25
LINKER-MM4
NCT05828511
P1/2Active, not recruitingMultiple Myeloma1482035-11-02 (+4 mo)